SCHEMBL266071

SCHEMBL266071

O=C(Nc1ccccc1C(=O)N/N=C/c1cccc(O)c1)c1cccc(F)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.62
NPC1 O15118 7/20 0.61
RAB9A P51151 7/20 0.61
MAPT P10636 7/20 0.61
PKM P14618 6/20 0.61
KMT2A Q03164 6/20 0.55
MEN1 O00255 5/20 0.55
CASP3 P42574 1/20 0.55
SENP8 Q96LD8 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
SENP6 Q9GZR1 1/20 0.55
ALDH1A1 P00352 2/20 0.54
SMN1; SMN2 Q16637 5/20 0.54
HPGD P15428 2/20 0.54
KDM4E B2RXH2 1/20 0.54
ALOX12 P18054 1/20 0.54
POLB P06746 3/20 0.54
TDP1 Q9NUW8 2/20 0.54
CTDSP1 Q9GZU7 1/20 0.54
CYP2D6 P10635 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266072 1.00 NPSR1 (0.62) NPSR1NPC1RAB9AMAPTPKM
SCHEMBL266682 0.94 NPC1 (0.62) NPSR1NPC1RAB9AMAPTPKM
SCHEMBL266683 0.94 NPC1 (0.62) NPSR1NPC1RAB9AMAPTPKM
SCHEMBL265910 0.90 MAPT (0.64) NPSR1NPC1RAB9AMAPTPKM
SCHEMBL266888 0.90 RAB9A (0.77) NPSR1NPC1RAB9AMAPTPKM
SCHEMBL266889 0.90 RAB9A (0.77) NPSR1NPC1RAB9AMAPTPKM
SCHEMBL265909 0.90 MAPT (0.64) NPSR1NPC1RAB9AMAPTPKM
SCHEMBL266751 0.90 RAB9A (0.69) NPSR1NPC1RAB9AMAPTPKM
SCHEMBL266752 0.90 RAB9A (0.69) NPSR1NPC1RAB9AMAPTPKM
SCHEMBL265442 0.89 RAB9A (0.56) NPSR1NPC1RAB9AMAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 NPSR1 390/4885NPC1 102/4885RAB9A 883/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 NPSR1 264/4885NPC1 115/4885RAB9A 1362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.